<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01557023</url>
  </required_header>
  <id_info>
    <org_study_id>EF 124 NINA</org_study_id>
    <nct_id>NCT01557023</nct_id>
  </id_info>
  <brief_title>Clinical Trial With Combination of Dienogest/Ethytnilestradiol and Drosperidona/Ethyniestradiol</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eurofarma Laboratorios S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eurofarma Laboratorios S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will study the percentage of women with at least one occurrence of intracyclic
      bleeding (bleeding and/or spotting) during the cycles 2 and 3 of treatment with test or
      reference drug.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Change Company strategy
  </why_stopped>
  <start_date type="Anticipated">July 1, 2013</start_date>
  <completion_date type="Anticipated">December 1, 2014</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of intracyclic bleeding and/or spotting during the cycles 2 and 3 of treatment</measure>
    <time_frame>2 and 3 cycles (each cycle is 21 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of women with intracyclic bleeding during treatment cycles 2 to 7</measure>
    <time_frame>2 and 7 cycles (each cycle is 21 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Metrorrhagia</condition>
  <arm_group>
    <arm_group_label>dienogest 2 mg/ethynilestradiol 30 mcg;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Yasmin®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>barrier methods</intervention_name>
    <arm_group_label>dienogest 2 mg/ethynilestradiol 30 mcg;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>barrier methods</intervention_name>
    <arm_group_label>Yasmin®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sign, initial and date the informed consent form;

          -  Female patients, with child bearing potential, aged 18 to 35 years;

          -  Have indication to receive progesterone and estrogen-based low oral hormone treatment
             for at least 7 cycles (approximately 7 months) for birth control;

          -  Be able to comply with the study protocol;

          -  Show normal result in cervical-vaginal cytology conducted up to 3 months before study
             enrollment or be willing to repeat the screening visit test, which result must also be
             normal;

          -  Be willing to use one of the study drugs

        Exclusion Criteria:

          -  Is pregnant or breastfeeding, suspecting to be or planning to get pregnant;

          -  Patients currently using oral contraceptives with drospirenone 3 mg/ ethynilestradiol
             30 mcg or dianogest 2 mg/ ethynilestradiol 30 mcg.

          -  Have history of gynecologic surgery such as hysterectomy, total oophorectomy or tubal
             ligation;

          -  Smoke over 10 cigarettes a day;

          -  Have any severe comorbidities (at the investigator's criteria), including bowel
             inflammatory disease

          -  Have hypertension, showing at least one of the following conditions:

        Systolic pressure &gt;140 mm Hg or diastolic pressure &gt;90 mm Hg in sitting position;

          -  Current use of pharmacological treatment for hypertension;

          -  Show history or currently have venous or arterial thromboembolism;

          -  History of breast or genital cancer;

          -  Have obesity (BMI &gt;30 kg/m2);

          -  Have liver disease or changed lab values;

          -  Currently have dysplasia or malignancy in cervical-vaginal cytology;

          -  Concomitantly use CYP3A4 metabolizing drugs or drugs causing drug interaction with
             other study drugs;

          -  History of abortion one (1) month before study enrollment;

          -  History of childbirth or breastfeeding 3 months before study enrollment;

          -  Have hypersensitivity to any of the study drug components;

          -  Patients with long-term disability, who have undergone a major surgery or any surgery
             in legs or major traumatism in the last 6 months;

          -  Have current diagnosis of sexually transmitted disease;

          -  Have used injectable hormones 3 months before study enrollment;

          -  Have used hormone implant 6 months before study enrollment;

          -  Have participated in another clinical trial in the last 12 months.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Instituto de Saúde e Bem Estar da Mulher</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2012</study_first_submitted>
  <study_first_submitted_qc>March 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2012</study_first_posted>
  <last_update_submitted>September 19, 2017</last_update_submitted>
  <last_update_submitted_qc>September 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metrorrhagia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dienogest</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

